Yu, W., Kong, J., Zheng, F., Mo, X., Zhang, X., Xu, L., . . . Wang, Y. Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy. Taylor & Francis Group.
Chicago Style (17th ed.) CitationYu, Wen-Jing, et al. Treatment of Minimal Residual Disease in Myeloid Malignancies After Allo-HSCT with Venetoclax-based Regimens in Patients Ineligible for or Failed in the Immunotherapy. Taylor & Francis Group.
MLA (9th ed.) CitationYu, Wen-Jing, et al. Treatment of Minimal Residual Disease in Myeloid Malignancies After Allo-HSCT with Venetoclax-based Regimens in Patients Ineligible for or Failed in the Immunotherapy. Taylor & Francis Group.
Warning: These citations may not always be 100% accurate.